Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

DrugBank

FEBRUARY 26, 2025

Advances in genetic engineering have enabled researchers to enhance bacteriophage efficacy and overcome bacterial resistance mechanisms. Developing Antimicrobial Peptides and Biomolecules In addition to traditional small-molecule antibiotics, researchers are exploring the potential of antimicrobial peptides (AMPs) and other biomolecules.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 27, 2020

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. platform and its large-capacity VV Cop TK”RR” oncolytic virus, engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s n-CoDeR/F.I.R.S.T.

Trials 52

Trials Clinical Trials Therapies RNA 52

Codon

DECEMBER 12, 2024

It’s difficult to imagine any evolutionary path that could “reverse” the tangled molecules of life into their mirrored forms, because incremental mutations which swap out a few chiral molecules for their enantiomers would impair or kill the cell. The report maps out at least three options.

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

AUGUST 3, 2021

whose proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. The company announced the acquisition of Protomer Technologies Inc., Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Production 52

Production Marketing Research Treatment 52

Codon

MARCH 26, 2023

Link Biological Engineering *Photosynthesis re-wired on the pico-second timescale. Link *Design of Four Small-Molecule-Inducible Systems in the Yeast Chromosome, Applied to Optimize Terpene Biosynthesis. Link A Genetic Programming Approach to Engineering MRI Reporter Genes. Metabolic Engineering. Antika T.R.

DNA 52

DNA Engineering RNA Science 52

Drug Target Review

DECEMBER 4, 2024

The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.

Pharmacokinetics 122

Pharmacokinetics Small Molecule Therapies Immune Response 122

Drug Target Review

NOVEMBER 7, 2024

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52

Disease Immune Response Regulations Engineering 52

Drug Target Review

DECEMBER 11, 2024

Discovering and optimising potent therapeutics that direct the immune response against these targets. This requires a deep understanding of how the key components of the immune system – antibodies and TCRs – recognise and interact with their targets on cancer cells. Nature Reviews Drug Discovery. Science Advances.

Immune Response 52

Immune Response Engineering Therapies Small Molecule 52

Codon

APRIL 16, 2023

Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. Skin microbes can trigger strong immune responses. In other words: Brush some engineered bacteria on the skin, and they activate the immune system to go fight a tumor. Metabolic Engineering. Wichmann J.

Engineering 52

Engineering DNA RNA Science 52